Funding for this research was provided by:
Spanish Ministry of Science and Innovation, Instituto Carlos III (PI17/00056)
Text and Data Mining valid from 2019-05-06
Received: 7 February 2019
Accepted: 12 April 2019
First Online: 6 May 2019
Ethics approval and consent to participate
: This study is approved by the Ethical Committee for Clinical Research (in Spanish, <i>Comité Ético de Investigación Clínica</i>) from the Hospital de la Santa Creu i Sant Pau, project number IIBSP-RID-2017-107. Protocol version 1, 14th February 2018.Central Clinical Research and Clinical Trials Unit (CCRCTU), Research Institute of the Hospital de Sant Pau, will monitor through periodic visits the correct progression of the project, alerting from protocol deviations. They will be constantly aware of every single step of the project.All participants will receive extended information about the study and must give their written informed consent prior to participate in the study. This study does not pose any risk to the participants.
: Written informed consent from participants will be obtained prior to the inclusion to the study.
: MJP has received honoraria as academic from Lundbeck. JDA has received consulting and/or lecture honoraria from Lundbeck, Pfizer and Qualigen. NC declares that he has received honoraria as consultant, advisor or CME speaker from Janssen, Lundbeck, Pfizer, Exeltis and MSD. The rest of the authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.